CR20220041A - Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab - Google Patents
Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimabInfo
- Publication number
- CR20220041A CR20220041A CR20220041A CR20220041A CR20220041A CR 20220041 A CR20220041 A CR 20220041A CR 20220041 A CR20220041 A CR 20220041A CR 20220041 A CR20220041 A CR 20220041A CR 20220041 A CR20220041 A CR 20220041A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibody
- crovalimab
- dose
- dosage
- administration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con una dosis y régimen de administración de anticuerpos anti-C5, particularmente del anticuerpo anti-C5 Crovalimab, para usarse en un método de tratamiento o prevenir la enfermedad relacionada con C5 en un sujeto, que incluye hemoglobinuria nocturna paroxismal (PNH). El régimen de dosificación y tratamiento de la presente invención incluye la administración de un anticuerpo anti-C5, preferiblemente del anticuerpo anti-C5 Crovalimab, con dosis de carga seguido por la administración de (a) dosis de mantenimiento(s) del anticuerpo anti-C5 al sujeto, donde la dosis de carga administrada inicialmente es proporcionada intravenosamente al sujeto y la carga restante y las dosis de mantenimiento se administran subcutáneamente en una dosis baja como la dosis de carga administrada intravenosamente.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19189442 | 2019-07-31 | ||
EP20174790 | 2020-05-14 | ||
EP20179591 | 2020-06-11 | ||
PCT/EP2020/071555 WO2021019036A1 (en) | 2019-07-31 | 2020-07-30 | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220041A true CR20220041A (es) | 2022-03-02 |
Family
ID=71846415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220041A CR20220041A (es) | 2019-07-31 | 2020-07-30 | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220275070A1 (es) |
EP (1) | EP4003409A1 (es) |
JP (2) | JP7437261B2 (es) |
KR (2) | KR20210016333A (es) |
CN (2) | CN114929273A (es) |
AU (1) | AU2020322165A1 (es) |
CA (1) | CA3144923A1 (es) |
CR (1) | CR20220041A (es) |
IL (1) | IL288600A (es) |
MX (1) | MX2022001154A (es) |
TW (1) | TW202120125A (es) |
WO (1) | WO2021019036A1 (es) |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
EP2113516B1 (en) | 2000-10-10 | 2014-05-21 | Genentech, Inc. | Antibodies against C5 inhibiting type II endothelial cell activation |
ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
EP2815766B1 (en) | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
PT2894165T (pt) | 2008-11-10 | 2023-03-17 | Alexion Pharma Inc | Métodos e composições para o tratamento de distúrbios associados ao complemento |
LT3233921T (lt) | 2014-12-19 | 2021-12-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antikūnai ir panaudojimo būdai |
TWI747936B (zh) | 2015-12-18 | 2021-12-01 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
MA53248A (fr) | 2016-01-25 | 2022-02-16 | Takeda Pharmaceuticals Co | Anticorps anti-c5 à commutation ph améliorée |
KR20230043247A (ko) * | 2017-01-31 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
CN111868081A (zh) * | 2017-10-26 | 2020-10-30 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
-
2020
- 2020-07-30 WO PCT/EP2020/071555 patent/WO2021019036A1/en unknown
- 2020-07-30 CN CN202080054557.7A patent/CN114929273A/zh active Pending
- 2020-07-30 KR KR1020207030736A patent/KR20210016333A/ko not_active Application Discontinuation
- 2020-07-30 TW TW109125890A patent/TW202120125A/zh unknown
- 2020-07-30 AU AU2020322165A patent/AU2020322165A1/en active Pending
- 2020-07-30 EP EP20747415.6A patent/EP4003409A1/en active Pending
- 2020-07-30 US US17/630,046 patent/US20220275070A1/en active Pending
- 2020-07-30 KR KR1020247006223A patent/KR20240033090A/ko active Search and Examination
- 2020-07-30 CR CR20220041A patent/CR20220041A/es unknown
- 2020-07-30 CN CN202210578978.0A patent/CN115068604A/zh active Pending
- 2020-07-30 MX MX2022001154A patent/MX2022001154A/es unknown
- 2020-07-30 JP JP2020129462A patent/JP7437261B2/ja active Active
- 2020-07-30 CA CA3144923A patent/CA3144923A1/en active Pending
-
2021
- 2021-12-01 IL IL288600A patent/IL288600A/en unknown
-
2022
- 2022-03-09 JP JP2022036164A patent/JP2022101535A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202120125A (zh) | 2021-06-01 |
MX2022001154A (es) | 2022-02-22 |
JP2021038198A (ja) | 2021-03-11 |
CN114929273A (zh) | 2022-08-19 |
US20220275070A1 (en) | 2022-09-01 |
EP4003409A1 (en) | 2022-06-01 |
CN115068604A (zh) | 2022-09-20 |
JP2022101535A (ja) | 2022-07-06 |
AU2020322165A1 (en) | 2022-01-06 |
IL288600A (en) | 2022-02-01 |
KR20210016333A (ko) | 2021-02-15 |
CA3144923A1 (en) | 2021-02-04 |
JP7437261B2 (ja) | 2024-02-22 |
WO2021019036A1 (en) | 2021-02-04 |
KR20240033090A (ko) | 2024-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2016000302A (es) | Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
EA201892190A1 (ru) | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы | |
MX2015012547A (es) | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. | |
CO2017008395A2 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol | |
CO2021006290A2 (es) | Dosificación subcutánea y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh) | |
CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
CR20220041A (es) | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab | |
MX2022001153A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
CL2022001079A1 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
BR112022018315A2 (pt) | Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina | |
CO2020001314A2 (es) | Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante | |
BR112018072183A2 (pt) | composição farmacêutica, e, método para prevenir uma doença de pele | |
AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
AR099907A1 (es) | Composición farmacéutica usada en la prevención y/o el tratamiento de enfermedades causadas y/o agravadas por una disminución o deficiencia de la actividad del factor de coagulación sanguínea viii y/o del factor de coagulación sanguínea viii activado | |
AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente |